# A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations

> **NCT07685444** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Lingyi Biotech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **GENETIC:** LY-N001 Injection

## Key facts

- **NCT ID:** NCT07685444
- **Lead sponsor:** Lingyi Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2028-07-07
- **Final completion:** 2032-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685444, "A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*